Overview

A Study of IDN-6556 in Subjects With Liver Cirrhosis

Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This is a multicenter study to see if treatment with IDN-6556 can help improve the liver function of patients with liver cirrhosis with Model for End-Stage Liver Disease scores between 11-18.
Phase:
Phase 2
Details
Lead Sponsor:
Conatus Pharmaceuticals Inc.